Laetitia Koppe1,2, Denis Fouque3,4, Christophe O Soulage4. 1. Department Nephrology, Centre Hospitalier Lyon Sud, 69495, Pierre-Benite, France. laetitia.koppe@chu-lyon.fr. 2. Univ. Lyon, CarMeN lab, INSA-Lyon, INSERM U1060, INRA, Université Claude Bernard Lyon 1, 69621, Villeurbanne, France. laetitia.koppe@chu-lyon.fr. 3. Department Nephrology, Centre Hospitalier Lyon Sud, 69495, Pierre-Benite, France. 4. Univ. Lyon, CarMeN lab, INSA-Lyon, INSERM U1060, INRA, Université Claude Bernard Lyon 1, 69621, Villeurbanne, France.
Abstract
PURPOSE OF REVIEW: Chronic kidney disease (CKD) is characterized by the accumulation of uremic retention solutes (URS) and is associated with perturbations of glucose homeostasis even in absence of diabetes. The underlying mechanisms of insulin resistance, β cell failure, and increase risk of diabetes in CKD, however, remain unclear. Metabolomic studies reported that some metabolites are similar in CKD and diabetic kidney disease (DKD) and contribute to the progression to end-stage renal disease. We attempted to discuss the mechanisms involved in the disruption of carbohydrate metabolism in CKD by focusing on the specific role of URS. RECENT FINDINGS: Recent clinical data have demonstrated a defect of insulin secretion in CKD. Several studies highlighted the direct role of some URS (urea, trimethylamine N-oxide (TMAO), p-cresyl sulfate, 3-carboxylic acid 4-methyl-5-propyl-2-furan propionic (CMPF)) in glucose homeostasis abnormalities and diabetes incidence. Gut dysbiosis has been identified as a potential contributor to diabetes and to the production of URS. The complex interplay between the gut microbiota, kidney, pancreas β cell, and peripheral insulin target tissues has brought out new hypotheses for the pathogenesis of CKD and DKD. The characterization of intestinal microbiota and its associated metabolites are likely to fill fundamental knowledge gaps leading to innovative research, clinical trials, and new treatments for CKD and DKD.
PURPOSE OF REVIEW: Chronic kidney disease (CKD) is characterized by the accumulation of uremic retention solutes (URS) and is associated with perturbations of glucose homeostasis even in absence of diabetes. The underlying mechanisms of insulin resistance, β cell failure, and increase risk of diabetes in CKD, however, remain unclear. Metabolomic studies reported that some metabolites are similar in CKD and diabetic kidney disease (DKD) and contribute to the progression to end-stage renal disease. We attempted to discuss the mechanisms involved in the disruption of carbohydrate metabolism in CKD by focusing on the specific role of URS. RECENT FINDINGS: Recent clinical data have demonstrated a defect of insulin secretion in CKD. Several studies highlighted the direct role of some URS (urea, trimethylamine N-oxide (TMAO), p-cresyl sulfate, 3-carboxylic acid 4-methyl-5-propyl-2-furan propionic (CMPF)) in glucose homeostasis abnormalities and diabetes incidence. Gut dysbiosis has been identified as a potential contributor to diabetes and to the production of URS. The complex interplay between the gut microbiota, kidney, pancreas β cell, and peripheral insulin target tissues has brought out new hypotheses for the pathogenesis of CKD and DKD. The characterization of intestinal microbiota and its associated metabolites are likely to fill fundamental knowledge gaps leading to innovative research, clinical trials, and new treatments for CKD and DKD.
Authors: Sunny Eloot; Eva Schepers; Daniela V Barreto; Fellype C Barreto; Sophie Liabeuf; Wim Van Biesen; Francis Verbeke; Griet Glorieux; Gabriel Choukroun; Ziad Massy; Raymond Vanholder Journal: Clin J Am Soc Nephrol Date: 2011-05-26 Impact factor: 8.237
Authors: Fredrik Bäckhed; Jill K Manchester; Clay F Semenkovich; Jeffrey I Gordon Journal: Proc Natl Acad Sci U S A Date: 2007-01-08 Impact factor: 11.205
Authors: Ting Jia; Ulf Risérus; Hong Xu; Bengt Lindholm; Johan Ärnlöv; Per Sjögren; Tommy Cederholm; Tobias E Larsson; Talat Alp Ikizler; Juan J Carrero Journal: J Clin Endocrinol Metab Date: 2014-11-27 Impact factor: 5.958
Authors: David Ríos-Covián; Patricia Ruas-Madiedo; Abelardo Margolles; Miguel Gueimonde; Clara G de Los Reyes-Gavilán; Nuria Salazar Journal: Front Microbiol Date: 2016-02-17 Impact factor: 5.640
Authors: Monika A Niewczas; Tammy L Sirich; Anna V Mathew; Jan Skupien; Robert P Mohney; James H Warram; Adam Smiles; Xiaoping Huang; Walker Walker; Jaeman Byun; Edward D Karoly; Elizabeth M Kensicki; Gerard T Berry; Joseph V Bonventre; Subramaniam Pennathur; Timothy W Meyer; Andrzej S Krolewski Journal: Kidney Int Date: 2014-01-15 Impact factor: 10.612
Authors: Wojciech Wołyniec; Katarzyna Kasprowicz; Joanna Giebułtowicz; Natalia Korytowska; Katarzyna Zorena; Maria Bartoszewicz; Patrycja Rita-Tkachenko; Marcin Renke; Wojciech Ratkowski Journal: Int J Environ Res Public Health Date: 2019-10-28 Impact factor: 3.390